Play all audios:
Access through your institution Buy or subscribe Katsinelos P _et al_. (2005) High-dose allopurinol for prevention of post-ERCP pancreatitis: a prospective randomized double-blind controlled
trial. _Gastrointest Endosc_ 61: 407–415 Allopurinol inhibits the generation of oxygen-derived free radicals and it has been postulated that this xanthine oxidase inhibitor might prevent
post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. Despite promising results in animal models, prospective studies using a standard dose of allopurinol have not been
successful in humans. In a prospective, randomized, double-blind, placebo-controlled trial, Katsinelos and colleagues found that in patients given high-dose, oral allopurinol before
treatment, post-ERCP pancreatitis occurred less frequently. This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to
this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy
now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact
customer support RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Does high-dose allopurinol prevent post-ERCP pancreatitis?. _Nat Rev Gastroenterol
Hepatol_ 2, 202–203 (2005). https://doi.org/10.1038/ncpgasthep0160 Download citation * Issue Date: 01 May 2005 * DOI: https://doi.org/10.1038/ncpgasthep0160 SHARE THIS ARTICLE Anyone you
share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the
Springer Nature SharedIt content-sharing initiative